EPS for iClick Interactive Asia Group Limited (ICLK) Expected At $-0.07; VIVUS, Inc. (VVUS) Had 2 Bulls

May 18, 2018 - By Michael Collier

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus has $4 highest and $1.50 lowest target. $2.77’s average target is 343.70% above currents $0.6243 stock price. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, August 5 by Zacks. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report. As per Thursday, November 5, the company rating was upgraded by WallachBeth Capital. See VIVUS, Inc. (NASDAQ:VVUS) latest ratings:

Analysts expect iClick Interactive Asia Group Limited (NASDAQ:ICLK) to report $-0.07 EPS on May, 23 before the open.After having $-0.32 EPS previously, iClick Interactive Asia Group Limited’s analysts see -78.13% EPS growth. The stock decreased 1.25% or $0.09 during the last trading session, reaching $7.11. About 112,161 shares traded. iClick Interactive Asia Group Limited (NASDAQ:ICLK) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

iClick Interactive Asia Group Limited, together with its subsidiaries, provides online marketing services in the People's Republic of China, Hong Kong, and internationally. The company has market cap of $340.37 million. The firm offers mobile audience solutions, which are non-search engine marketing solutions designed to identify, engage, and activate audience on mobile apps, and monitor and measure the results of online marketing activities on such channels; and other solutions that focuses on identifying, engaging, and activating audience on non-mobile app content distribution channels comprising PC banner displays, PC video advertisements, and search engine marketing, as well as technology development services. It currently has negative earnings. It sells its solutions by entering into marketing campaign contracts with marketers or marketing agencies.

More news for iClick Interactive Asia Group Limited (NASDAQ:ICLK) were recently published by: Nasdaq.com, which released: “iClick Interactive Asia Group Limited to Report First Quarter 2018 Financial Results on Wednesday, May 23, 2018” on May 08, 2018. Nasdaq.com‘s article titled: “iClick Interactive Asia Group Limited Files 2017 Annual Report on Form 20-F” and published on April 20, 2018 is yet another important article.

Investors sentiment increased to 0.57 in Q4 2017. Its up 0.04, from 0.53 in 2017Q3. It improved, as 9 investors sold VIVUS, Inc. shares while 21 reduced holdings. 8 funds opened positions while 9 raised stakes. 25.91 million shares or 20.65% less from 32.65 million shares in 2017Q3 were reported. The Germany-based Deutsche Bancorp Ag has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Bancshares Of America De reported 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Next Fincl Grp reported 38,253 shares stake. Sei Invs has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Plante Moran Financial Advsr Lc reported 190 shares. Financial Architects accumulated 4,000 shares. D E Shaw Inc holds 325,769 shares or 0% of its portfolio. Acadian Asset Mgmt Ltd Liability reported 2.68 million shares stake. Winfield Associate holds 0% or 400 shares in its portfolio. Moreover, Blackrock has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 2.31M shares. Sg Americas Securities Limited Com holds 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 33,995 shares. Hanson Mcclain, California-based fund reported 250 shares. Group One Trading Limited Partnership stated it has 17,069 shares. Elkhorn Prns Ltd Partnership holds 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 11,300 shares. 24,500 are owned by Maple Capital.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $66.21 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

The stock decreased 5.41% or $0.0357 during the last trading session, reaching $0.6243. About 3.12M shares traded or 238.43% up from the average. VIVUS, Inc. (NASDAQ:VVUS) has declined 65.45% since May 18, 2017 and is downtrending. It has underperformed by 77.00% the S&P500.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.